IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Filvaroff)	A . 11 1. 1646
Application No.: 10/617,573)	Art Unit: 1646
Filed: July 11, 2003)	Examiner: Jiang, Dong
)	
Title Pharmaceutical compositions, kits and therapeutic)	
uses of antagonist antibodies to IL-17E)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop ____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent, except for pending U.S. applications and issued U.S. patents, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):		
		(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR
		(2)	It is being filed within 3 months of entry of a national stage OR
		(3)	It is being filed before the mail date of the first Office Action on the merits OR
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on th merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:		
		a certif	ication as specified in §1.97(e) is provided below; or
			f \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the nt of other papers filed together with this statement.
	37 C.F.R. $\S1.97(d)$. If this statement is being filed after the mailing date of the earlier of a final offic action under $\S1.113$ or a notice of allowance under $\S1.311$, but before payment of the issue fee, then		
	A.	a certif	ication as specified in §1.97(e) is completed below; and
	В.	a petition	on under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted th; and
	C.		\$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the at of other papers filed together with this statement.
	<i>Fee Authorization</i> . The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 50-4634 (Docket No. 123851-181748)		
			Respectfully submitted, GOODWIN PROCTER LLP
Dated:		Novemb	Der 24, 2008 By: Jeffrey C. Talkington, Reg. No. 58,381
	in Proct		
	mmonw Park, CA	ealth Dr A 94025	ive
(650) 7	52-3100 ner No. 7	1	
	10. /	1010	